Assertio Holdings, Inc. to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
July 24, 2023 08:30 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., July 24, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings Joins Russell 3000® Index
June 26, 2023 07:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., June 26, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company, today announced that it has joined the...
Assertio Reports First Quarter 2023 Financial Results, Raises Full Year 2023 Outlook
May 09, 2023 07:15 ET
|
Assertio Holdings, Inc.
Net Product Sales Increase 18% Year-Over-Year Raises Full Year Outlook to Net Product Sales of $157 to $167 Million, Adjusted EBITDA $90 to $98 Million To Acquire Spectrum...
Assertio Holdings, Inc. Updates First Quarter 2023 Financial Results Call Time to Tuesday, May 9, 2023 at 11:30 am Eastern Time
May 05, 2023 08:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., May 05, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Report First Quarter 2023 Financial Results on Tuesday, May 9, 2023
April 27, 2023 09:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 27, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
April 25, 2023 06:00 ET
|
Assertio Holdings, Inc.; Spectrum Pharmaceuticals, Inc.
Complementary Commercial Growth Platforms Anticipated to Accelerate ROLVEDON™ (eflapegrastim-xnst) Injection Profitability and Diversify Revenue Streams Combination of Assertio’s Omni-Channel...
Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
April 24, 2023 09:00 ET
|
Assertio Holdings, Inc.
SYMPAZAN (clobazam) oral CIV film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and older Oral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 07, 2023 16:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., April 07, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Fourth Quarter and Full Year 2022 Financial Results
March 08, 2023 16:01 ET
|
Assertio Holdings, Inc.
Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from...
Assertio Appoints Dr. Howard Franklin as Senior Vice President, Medical
March 06, 2023 09:00 ET
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., March 06, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...